FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Melinda VanRoey

Research Profile

Living Beings

Disorders

Chemicals & Drugs

Anatomy

Procedures

Co-author Network

Publications

TOP 3
Betty Li; Andrew Simmons; Thomas Du; Carol Lin; Marina Moskalenko; Melissa Gonzalez-Edick; Melinda VanRoey; Karin Jooss
Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Shanthi Ganesh; M Gonzalez-Edick; D Gibbons; Y Ge; Melinda VanRoey; M Robinson; Karin Jooss
Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
Michael Robinson; Betty Li; Ying Ge; Derek Ko; Satya Yendluri; Thomas C Harding; Melinda VanRoey; Katherine R Spindler; Karin Jooss
Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Melinda VanRoey (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Betty Li; Andrew Simmons; Thomas Du; Carol Lin; Marina Moskalenko; Melissa Gonzalez-Edick; Melinda VanRoey; Karin Jooss
Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Clinical immunology (Orlando, Fla.) 2009;133(2):184-97.
2009: Shanthi Ganesh; M Gonzalez-Edick; D Gibbons; Y Ge; Melinda VanRoey; M Robinson; Karin Jooss
Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
Cancer gene therapy 2009;16(5):383-92.
2009: Michael Robinson; Betty Li; Ying Ge; Derek Ko; Satya Yendluri; Thomas C Harding; Melinda VanRoey; Katherine R Spindler; Karin Jooss
Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors.
Journal of virology 2009;83(8):3450-62.
2009: Betty Li; Melinda VanRoey; Changyu Wang; Tseng-hui Timothy Chen; Alan Korman; Karin Jooss
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(5):1623-34.
2008: Betty Li; Melinda VanRoey; Frederic Triebel; Karin Jooss
Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3545-54.
2008: Jian Min Lin; Betty Li; Eric Rimmer; Melinda VanRoey; Karin Jooss
Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
Experimental hematology 2008;36(3):319-28.
2007: Betty Li; Jianmin Lin; Melinda VanRoey; Maria Jure-Kunkel; Karin Jooss
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Clinical immunology (Orlando, Fla.) 2007;125(1):76-87.
2007: Andrew D Simmons; Betty Li; Melissa Gonzalez-Edick; Carol Lin; Marina Moskalenko; Thomas Du; Jennifer Creson; Melinda VanRoey; Karin Jooss
GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.
Cancer immunology, immunotherapy : CII 2007;56(10):1653-65.
2007: Jianmin Fang; Saili Yi; Andrew Simmons; Guang Huan Tu; Minh Nguyen; Thomas C Harding; Melinda VanRoey; Karin Jooss
An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo.
Molecular therapy : the journal of the American Society of Gene Therapy 2007;15(6):1153-9.
2007: Shanthi Ganesh; Melissa Gonzalez-Edick; Neeraja Idamakanti; Marina Abramova; Melinda VanRoey; Michael Robinson; Chae-Ok Yun; Karin Jooss
Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.
Cancer research 2007;67(9):4399-407.
2007: Betty Li; Melinda VanRoey; Karin Jooss
Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
Clinical immunology (Orlando, Fla.) 2007;123(2):155-65.
2006: Betty Li; Alshad Lalani; Thomas C Harding; Bo Luan; Kathryn Koprivnikar; Guang Huan-Tu; Rodney A Prell; Melinda VanRoey; Andrew D Simmons; Karin Jooss
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(22):6808-16.
2006: Rodney A Prell; Lisa Gearin; Andrew Simmons; Melinda VanRoey; Karin Jooss
The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration.
Cancer immunology, immunotherapy : CII 2006;55(10):1285-93.
2006: Thomas C Harding; Alshad Lalani; Byron N Roberts; Satya Yendluri; Bo Luan; Kathryn Koprivnikar; Melissa Gonzalez-Edick; Guang Huan-Tu; Randy Musterer; Melinda VanRoey; Tomoko Ozawa; Richard A LeCouter; Dennis Deen; Peter J Dickinson; Karin Jooss
AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13(5):956-66.
2005: Yuanhao Li; Neeraja Idamakanti; Trini Arroyo; Steve Thorne; Tony Reid; Scott Nichols; Melinda VanRoey; Gail T Colbern; Natalie Nguyen; Orlena Tam; Peter Working; De-Chao Yu
Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(24 Pt 1):8845-55.
2005: JianMin Lin; Alshad Lalani; Thomas C Harding; Melissa Gonzalez; Wei-Wei Wu; Bo Luan; Guang Huan Tu; Kathryn Koprivnikar; Melinda VanRoey; Yulong He; Kari Alitalo; Karin Jooss
Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.
Cancer research 2005;65(15):6901-9.
2005: Jianmin Fang; Jing-Jing Qian; Saili Yi; Thomas C Harding; Guang Huan Tu; Melinda VanRoey; Karin Jooss
Stable antibody expression at therapeutic levels using the 2A peptide.
Nature biotechnology 2005;23(5):584-90.
2005: Rodney A Prell; Betty Li; Jian Min Lin; Melinda VanRoey; Karin Jooss
Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine.
Cancer research 2005;65(6):2449-56.
2004: Nagarajan Ramesh; Bahram Memarzadeh; Ying Ge; David Frey; Melinda VanRoey; Virginia Rojas; De-Chao Yu
Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;10(4):697-705.
2004: Alshad Lalani; Betty Chang; JianMin Lin; Scott S Case; Bo Luan; Wei-Wei Wu-Prior; Melinda VanRoey; Karin Jooss
Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;9(1):56-66.
2004: Thomas C Harding; Kathryn Koprivnikar; Guang Huan Tu; Nathalie Zayek; S Lew; A Subramanian; A Sivakumaran; David Frey; Kenneth Ho; Melinda VanRoey; Timothy C Nichols; Dwight A Bellinger; Satya Yendluri; J Waugh; J McArthur; Gabor Veres; Brian A Donahue
Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
Gene therapy 2004;11(2):204-13.